Oct 30, 2023
Tim Moran, President and CEO of Avertix, discusses the company's mission to revolutionize how heart attack survivors are cared for and supported. Targeting patients who have had one prior heart attack or instance of a prior acute coronary syndrome, this first-of-its-kind technology is implanted in patients to monitor for the onset of another heart attack. The device notifies the patient in real-time so they can seek care and minimize the effects of the attack. Work is underway for providing cloud connectivity to the device, allowing data to be shared with physicians and family members.
Tim explains, "So in our study, patients that had The Guardian product implanted, we were able to reduce their time to care from the onset of symptoms by almost eight times. So we got the time down on average to 1.6 hours from the onset of symptoms where they arrived at an emergency room and then ultimately could have therapeutic intervention like a stent put in, which ultimately would reperfuse them and get blood flowing again. So, it's a significant reduction in time to care."
"The other thing that was interesting is we found during our study that our device can detect silent heart attacks. So, patients that don't have any symptoms at all, and in those instances during the study, we detected 42 silent events. The patient had no symptoms. Our Guardian device, what will do when it detects a heart attack, it's going to vibrate in the patient's chest. Then, it will also give them a secondary and tertiary warning on a small handheld device that'll give them an audio-visual alert."
"So, we're building a brand-new category in cardiology right now. We're speaking to our clinicians, cardiologists, and electrophysiologists on a daily basis about our new technology. And if you look at our FDA label, it's been approved for any patient that has had one prior heart attack or any instance of a prior acute coronary syndrome. So that's a very, very large patient population."
"From there, physicians can decide within the patient population they're treating. A patient with a prior heart attack may have other comorbidities such as diabetes, high blood pressure, or a smoker, which puts them at even an elevated risk for a second event. And these are the patients that we're targeting with The Guardian."
#Avertix #HeartAttack #TheGuardian #HeartAttackSurvivors #Implantable #Cardiologists #Electrophysiologists
